Haemostasis & Coagulation disorders Objectives:

Similar documents
Coagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU

Dr. Rai Muhammad Asghar Associate Professor Head of Pediatric Department Rawalpindi Medical College

Bleeding Disorders: (Hemorrhagic Diatheses) Tests used to evaluate different aspects of hemostasis are the following:

Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN

HEME 10 Bleeding Disorders

Haemorrhagic Disorders. Dr. Bashar Department of Pathology Mosul Medical College

Platelet Disorders. By : Saja Al-Oran

Bleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph

Bleeding disorders. Hemostatic failure: Inappropriate and excessive bleeding either spontaneous or in response to injury.

BLEEDING DISORDERS Simple complement:

There are two main causes of a low platelet count

Bleeding and Thrombotic Disorders. Kristine Krafts, M.D.

Approach To A Bleeding Patient

ACQUIRED COAGULATION ABNORMALITIES

Moath Darweesh. Omar Sami. Saleem Khreisha. 1 P a g e

Bleeding Disorders HOPE Maram Al-anbar

BLEEDING (PLATELET) DISORDER. IAP UG Teaching slides

Easy bruising vs Coagulopathy

This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion

General approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013

Contents SECTION 1: PHYSIOLOGY OF BLOOD

Easy Bleeding General Presentation

Pathology note 8 BLEEDING DISORDER

Primary Exam Physiology lecture 5. Haemostasis

EDUCATIONAL COMMENTARY PLATELET DISORDERS

The LaboratoryMatters

Disseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS

Topics of today lectures: Hemostasis

Chapter 19. Hemostasis

Guidelines for Shared Care Centres and Community Staff

L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche

John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne

Chapter 3 Diseases of the Blood and Bloodforming Organs and Certain Disorders Involving the Immune Mechanism D50-D89

Congenital bleeding disorders

Coagulation an Overview Dr.Abdolreza Abdolr Afrasiabi Thal assem a & Heamophili hilia G ene i tic R esearc C en er Shiraz Medical Medic University

Hemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins

HENOCH SCHÖNLEIN PURPURA (VASCULAR PURPURA, ANAPHYLACTOID PURPURA) IN CHILDREN Single choice tests (SC)

PCCN Review Hematology

HAEMORRHAGIA Bleeding

Sysmex Educational Enhancement and Development No

LAMA SHATAT TTP, ITP, DIC

Hemostasis and. Blood Coagulation

A s doctors who care for children, we have a

UNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.

Clinical & Laboratory Assessment

Part IV Antithrombotics, Anticoagulants and Fibrinolytics

Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma

HAEMORRHAGIA Bleeding

COAGULATIONS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin)

Coagulation, Haemostasis and interpretation of Coagulation tests

Medical Surgical Review Handout- Hematology/Oncology 2016

Hemostasis Haemostasis means prevention of blood loss from blood vessels.

Disorders of the vessel wall. Dr. Klara Vezendi Szeged University Transfusiology Department

Physiology of. The Blood hemostasis. By prof. Israa f. jaafar

Routine preoperative coagulation tests: are they necessary?

Anatomy and Physiology

Blood Lecture Test Questions Set 2 Summer 2012

Disseminated Intravascular Coagulation (DIC) Seminar. Ron Kopilov 4 th year Medical Student, Tel Aviv University Internal Medicine A 8.3.

Blood clotting. Subsequent covalent cross-linking of fibrin by a transglutaminase (factor XIII) further stabilizes the thrombus.

Y. Helen Zhang, MD Andy Nguyen, MD 10/28/2012

Hemostatic System - general information

Bleeding and Haemostasis. Saman W.Boskani HDD, FIBMS Maxillofacial Surgeon

The Bleeding Patient. Sarah Stacey Charlotte Maxeke Johannesburg Hospital University of the Witwatersrand

Approach to disseminated intravascular coagulation

Blood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD

The importance of thrombocytopenia and its causes

Abnormal blood counts in children Dr Tina Biss Consultant Paediatric Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust

Hematologic Disorders. Assistant professor of anesthesia

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization

LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO.

FELINE HEMATOLOGY Inherited and Acquired Bleeding Disorders Marjory Brooks DVM, D.ACVIM

Introduction to coagulation and laboratory tests

MANAGEMENT OF COMMON BLEEDING DISORDERS. Auro Viswabandya Department of Haematology, CMC, Vellore

BLEEDING DISORDERS. JC Opperman 2012

Diagnosis of hypercoagulability is by. Molecular markers

Chapter 3. Haemostatic abnormalities in patients with liver disease

Chapter 19 Blood Lecture Outline

Idiopathic Thrombocytopenic Purpura

Acute Immune Thrombocytopenic Purpura (ITP) in Childhood

GUIDELINE: ASSESSMENT OF BRUISING & BLEEDING IN CHILDREN. All children in whom there is concern regarding bruising / bleeding

Hemostasis Haemostasis means prevention of blood loss from blood vessels.

Hemostasis. Clo)ng factors and Coagula4on NORMAL COAGULATION. Overview of blood coagula4on. The Cascade Theory 5/1/12. Clot

V.N. KARAZIN KHARKOV NATIONAL UNIVERSITY

WISKOTT-ALDRICH SYNDROME. An X-linked Primary Immunodeficiency

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III

CLINICAL FELLOWSHIP PROGRAM IN COAGULATION

Blood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th )

Disseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department

TREATMENT & MANAGEMENT OF VON WILLEBRAND DISEASE

r). SUPPLEMENTARY/SECOND OPPORTUNITY EXAMINATION PAPER nnmlbih UNIVERSITY Sophia Blaauw INSTRUCTIONS FACULTY OF HEALTH AND APPLIED SCIENCES

Update. Diagnostic. 1. Physiology. 2. Bleeding disorders

Index. Note: Page numbers of article titles are in boldface type.

Blood Components & Indications for Transfusion. Neda Kalhor

Document Title: Hemostasis: Platelet and Coagulation Disorders. Author(s): Joseph H. Hartmann (University of Michigan), DO 2012

HEMOSTASIS/THROMBOSIS II

Platelet disorders. Information for families. Great Ormond Street Hospital for Children NHS Foundation Trust

DIC. Bert Vandewiele Fellow Critical Care 23 May 2011

INHERITED COAGULOPATHY

Prothrombin Complex Concentrate- Octaplex. Octaplex

Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min

Transcription:

Haematology Lec. 1 د.ميسم مؤيد علوش Haemostasis & Coagulation disorders Objectives: - Define haemostasis and what are the major components involved in haemostasis? - How to assess the coagulation status? - List the main causes of bleeding? - List causes of bleeding due to vascular disorders? - List causes of thrombocytopenia? - -What is the meaning of immune thrombocytopenia purpura? Cause, pathogenesis,diagnosis? - Define post-transfusion purpura? Haemostasis: refers to the process whereby blood coagulation is initiated and terminated in a tightly regulated fashion, together with the removal (or fibrinolysis) of the clot as part of vascular remodeling. The five major components involved in haemostasis are: 1.Blood vessels:the endothelial cell forms a barrier between platelets and plasma clotting factors and the subendothelial connected tissues. Also they produce substances that have important role in coagulation. 2.Platelets: The main function of platelets is 1)-the formation of the primary haemostatic plug. 2)- release of platelet activating and procoagulant molecules. 3. Coagulation factors : include coagulation factors : ( I) fibrinogen,(ii) thrombin,v,vii,viii,ix,x,xi,xii,xiii& von Willebran Factor (VWF). Most coagulation factors are synthesized by hepatocytes.an exception is von Willebran Factor (VWF)which is synthesized by endothelial cells & megakaryocytes. The central event in the coagulation pathways is the production of thrombin, which acts upon fibrinogen to produce fibrin and thus the fibrin clot. This clot is further strengthened by the crosslinking action of factor XIII, which itself is activated by thrombin. 4. Coagulation inhibitors :Coagulation is normally localized to the site of injury &is controlled by a number of naturally occurring anticoagulant proteins,which are activated during 1

haemostasis.these include :Tissue factor pathway inhibitor(tfpi), Protien C, Protien S, Antithrombin. 5. Fibrinolysis : Fibrinolysis (like coagulation) is a normal haemostatic response to vascular injury. Plasminogen is converted to plasmin by tissue plasminogen activator (tpa) & urokinase (upa). Plasmin acts on fibrinogen &fibrin. Cleavage of peptide bonds in fibrin and fibrinogen produces fibrin degradation product s FDP. The involvement of blood vessels, platelets and blood coagulation in haemostasis 2

Fibrinolytic system Assessment of Coagulation Status: 1.Clinical assessment. 2.Labroratory assessment. Clinical Assessment: includes: - A personal history. - A family history. - A drug history. - Physical examination: should look for evidence of haemorrhage,including the presence of petechiae,ecchymoses or bruises. Purpura : bleeding into the skin &mucous membranes. Petechia: pinpoint cutaneous haemorrhages,a form of purpura. Ecchymosis: Large cutaneous haemorrhage,a form of purpura. Bruise : Bleeding into subcutaneous tissues Laboratory assessment of Coagulation: Tests used to evaluate different aspects of hemostasis are the following: Bleeding time: Prolongation generally indicates a defect in platelet numbers or function. Platelet counts: The reference range is 150 to 400 10 9 /L. Prothrombin time (PT): This assay tests the extrinsic and common coagulation pathways. A prolonged PT can result from 3

deficiency or dysfunction of: factor VII, factors X, V, prothrombin, or fibrinogen. Partial thromboplastin time (PTT): This assay tests the intrinsic and common clotting pathways. Prolongation of the PTT can be due to deficiency or dysfunction of: factors VIII, IX, XI, or XII, factors X, V, prothrombin, or fibrinogen..thrombin time (TT): is sensitive to a deficiency of fibrinogen or inhibition of thrombin by heparin or FDPs.. Others : Specific clotting factors assay. Fibrinogen assay. Fibrin degredation products (FDP). Platelet function tests. Bleeding Disorders: Excessive bleeding can result from: 1.Vascular disorders. 2. Thrombocytopenia or platelets dysfunction. 3. Defective coagulation. 4. Combinations of these. 1.Vascular disorders: The abnormality is either in the vessels themselves or in the perivascular connectivetissues. Usually no serious bleeding problems. Most often, they induce small hemorrhages in the skin or mucous membranes. The platelet count, bleeding time, and results of the coagulation tests (PT, PTT) are usually normal. -Vascular defects may be inherited or acquired. Inherited vascular disorders: Hereditary haemorrhagic telangiectasia: an autosomal dominant disorder characterized by dilated microvascular swellings develop in the skin, mucous membranes and internal organs. Connective tissue disorders : In the Ehlers-Danlos syndrome. 4

Acquired vascular defects: Simple easy bruising: is a common benign disorder which occurs in otherwise healthy women, especially those of childbearing age. Senile purpura: caused by atrophy of the supporting tissues of cutaneous blood vessels is seen mainly on dorsal aspects of the forearms and hands. Many bacterial, viral or rickettsial infections may cause purpura from vascular damage by the organism or as a result of immtme complex formation (e.g. measles, or meningococcal septicaemia). The Henoch-Schonlein syndrome: - usually seen in children,often follows an acute upper respiratory tract infection. -It is an immoglobulin A (IgA)-mediated vasculitis. - It is characterized by a purpuric rash, usually most prominent on the buttocks and,extensor surfaces of the lower legs and elbows. colicky abdominal pain (presumably due to focal hemorrhages into the gastrointestinal tract), polyarthralgia, and acute glomerulonephritis. - It is usually a self limiting condition but occasional patients develop renal failure. Scurvy. In vitamin C deficiency, perifollicular petechiae. Steroid purpura. is caused by defective vascular supportive tissue. 2. Thrombocytopenia Thrombocytopenia can be defined as platelet count of 100 10 9 /L or less. It is characterized by spontaneous skin purpura and mucosal haemorrhage and prolonged bleeding after trauma. -A prolonged bleeding time, and a normal PT and PTT. -Spontaneous bleeding becomes evident when counts fall below 20 10 9 cell/l -According to mechanism causes of thrombocytopenia are : 1-Failure of platelet production -2Increased destruction of platelets 5

3-Abnormal distribution of platelets 4-Dilutional loss 1.Failure of platelet production :. This is the most common cause of thrombocytopenia and is usually part of a generalized bone marrow failure. - Causes include:cytotoxic drugs, radiotherapy,aplastic anaemia, blood malignancies like Leukaemia, marrow infiltration ( e.g. carcinoma, lymphoma ),megaloblastic anaemia, HIV infection Selective megakaryocyte depression may result from drug toxicity or viral infection. Rarely it is congenital e.g. - Wiskott Aldrich syndrome (WAS) :thrombocytopenia with eczema,immune deficiency and small size platelets. Bernard Soulier syndrome - Autosomal recessive disease with thrombocytopenia, large platelet and platelet dysfunction. 2. Increased destruction of platelets: A)Immunologic destruction: - Autoimmune: immune thrombocytopenic purpura(itp), systemic lupus Erythematosus (SLE) -Alloimmune: post-transfusion and neonatal. -Drugs: heparin B ) Nonimmunologic destruction: -Disseminated intravascular coagulation (DIC). -Thrombotic thrombocytopenic purpura (TTP). 3.Abnormal distribution of platelets: -- Splenomegaly Thrombocytopenia, may develop in any patient with marked splenomegaly, Up to 90% of platelets may be sequestered in the spleen whereas normally the spleen contains one third of bodys 'platelets. 6

4.Dilutional loss:- Massive transfusions (more than 10 units over a 24-h period) can produce a dilutional thrombocytopenia. Blood stored for longer than 24 hours contains virtually no viable platelets ; thus, plasma volume and red cell mass are reconstituted by transfusion, but the number of circulating platelets is relatively reduced. Immune thrombocytopenic purpura (ITP): Platelet autoantibodies (usually IgG) result in the premature removal of platelets from the circulation by macrophages of the reticuloendothelial system, especially the spleen. The normal lifespan of a platelet is 7-10 days but in ITP this is reduced to a few hours. ITP may be chronic or acute :- Chronic immune thrombocytopenic purpura - A relatively common disorder. - The highest incidence is in adult aged 15-50 years, women more than men. -Treatment is usually needed. -It is either: 1. Idiopathic( usually). Or 2. occur in association with other diseases such as systemic lupus erythematosus (SLE), chronic lymphocytic leukaemia (CLL), lymphoma. Acute immune thrombocytopenic purpura: -Most common in children, with equal incidence in boys & girls. -Usually the episode follows vaccination or an infection such as chickenpox or infectious mononucleosis. -Spontaneous remission is usual & often no treatment is needed. Diagnosis of ITP :- 1.The platelet count is decreased. 2. The blood film shows reduced numbers of platelets. 3. The bone marrow shows normal or increased numbers of megakaryocytes. 4. Tests to detect autoantibodies. 7

Post-transfusion purpura Thrombocytopenia occurring approximately 10 days after a blood transfusion due to antibodies in the recipient developing against platelet antigen on transfused platelets (absent from the patient's own platelets). 8

9